Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of
the disease differ widely across the globe depending on access to early detection and …

Melanoma is the most aggressive and dangerous form of skin cancer that develops from
transformed melanocytes. It is crucial to identify melanoma at its early stages, in situ, as it is …

Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been
approved for the treatment of advanced melanoma. In the United States, ipilimumab has …

INTRODUCTION New therapies have been designed to stimulate the host's immune system
to fight cancer. Despite these exciting, recent successes, a large proportion of patients still …

Histone acetylation and deacetylation are important epigenetic mechanisms that regulate
gene expression and transcription. Histone deacetylase 6 (HDAC6) is a unique member of …

Characterizing the tumor immune microenvironment enables the identification of new
prognostic and predictive biomarkers, the development of novel therapeutic targets and …

Melanoma is a cancer that exhibits one of the most aggressive and heterogeneous features.
The incidence rate escalates. A high number of clones harboring various mutations …

Different clones, protocol conditions, instruments, and scoring/readout methods may pose
challenges in introducing different PD-L1 assays for immunotherapy. The diagnostic …

Background: Melanoma is highly immunogenic and therefore suitable for immunotherapy,
but the efficacy is limited by response rate. In several types of tumor, tumor mutation burden …

We report the results of 24 women, 50%(N= 12) with hormone receptor-positive breast
cancer and 50%(N= 12) with advanced triple-negative breast cancer, treated with …